COMMUNIQUÉS West-GlobeNewswire

The Ensign Group, Inc. Declares Quarterly Dividend of $0.0625 Per Share
19/09/2025
SAN JUAN CAPISTRANO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting
19/09/2025
Novel CB1 inhibitor Phase 1b data highlights lack of neuropsychiatric adverse events and favorable gastrointestinal tolerability SAN DIEGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye [...]
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
19/09/2025
Inmazeb ® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense , also known as Zaire ebolavirus Supply is being [...]
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
19/09/2025
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the National Comprehensive [...]
80,802 Orion Corporation A shares converted into B shares
19/09/2025
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 19 SEPTEMBER 2025 at 9.00 EEST 80,802 Orion Corporation A shares converted into B shares In accordance with [...]
Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders
19/09/2025
MINNEAPOLIS and BRISBANE, Australia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR , ASX: AVR), a global structural heart company committed to designing, [...]
Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension
19/09/2025
Idorsia receives approval from Swissmedic for JERAYGO ™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension. JERAYGO is a new oral antihypertensive [...]
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering
19/09/2025
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
18/09/2025
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2025 it granted stock options to purchase an aggregate of 39,790 shares of [...]
iCare ABA Therapy Launches With AI-Supported Model, Sparks Industry Debate on AI’s Role in Autism Care
18/09/2025
New York, NY, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The soft launch of iCare ABA Therapy is drawing attention across healthcare, real estate, and investment circles for one reason: its deliberate investment in artificial [...]
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/09/2025
FOSTER CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 966,000 [...]
Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
18/09/2025
Carlsbad, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
18/09/2025
CONSHOHOCKEN, Pa., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
18/09/2025
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative [...]
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
18/09/2025
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants
18/09/2025
REDWOOD CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on development of briquilimab, a novel antibody therapy [...]
NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting
18/09/2025
EMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company”) previously announced a one-time special cash dividend of $0.80 per share for the Company’s [...]
DBV Technologies annonce la démission d’un membre de son Conseil d’administration
18/09/2025
Châtillon, France, le 18 septembre 2025 DBV Technologies annonce la démission d’un membre de son Conseil d’administration DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (la “Société” ou “ [...]
DBV Technologies Announces Resignation of Board Member
18/09/2025
Châtillon, France, September 18, 2025 DBV Technologies Announces Resignation of Board Member DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage [...]

Pages